Allergy Therapeutics has announced that a full marketing authorisation application (MAA) has been submitted to the German health regulatory authority, the Paul Ehrlich Institute (PEI), in relation to the company’s short course duration grass pollen allergen immunotherapy, Grass MATA MPL. The application is supported by data from the pivotal G306 study and has been submitted under a national procedure process in Germany, with the formal review process expected to being shortly. Whilst we cannot p ....
